Product How it works Pricing Blog FAQ About Contact
SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ: SABS) revenue

SAB Biotherapeutics reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($1.3m).

SAB Biotherapeutics's revenue has fallen for 4 years in a row, and its best year of the last 6 was fiscal 2021. The biggest drop was in fiscal 2023, −90.6%.

Revenue, in millions of US dollars55.2202060.9202123.920222.220231.320240.02025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$0.0m−100.0%−$49.0m—
2024$1.3m−40.9%−$42.9m−3,244.9%
2023$2.2m−90.6%−$38.1m−1,700.6%
2022$23.9m−60.7%−$28.9m−121.0%
2021$60.9m+10.2%−$13.4m−22.0%
2020$55.2m—$20.6m37.2%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

SAB Biotherapeutics revenue compared with its sector

By revenue for its latest fiscal year, SAB Biotherapeutics ranks 417th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; SAB Biotherapeutics, −100.0%.

RankCompanyRevenueRevenue growth
415thRocket Pharmaceuticals$0.0m—
416thRevolution Medicines$0.0m—
417thSAB Biotherapeutics$0.0m−100.0%
418thSpruce Biosciences$0.0m−100.0%
419thScholar Rock$0.0m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of SAB Biotherapeutics

How much revenue did SAB Biotherapeutics make in fiscal 2025?
SAB Biotherapeutics reported revenue of $0.0m for fiscal 2025, compared with $1.3m in fiscal 2024.
What was the best year for revenue at SAB Biotherapeutics?
Of its last 6 fiscal years, fiscal 2021, with $60.9m.
Where does SAB Biotherapeutics rank in its sector by revenue?
It ranks 417th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for SAB Biotherapeutics come from?
From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on SAB Biotherapeutics: the SAB Biotherapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.